Association between COVID-19 vaccination and myasthenia gravis: A population-based, nested case-control study

Area of Science:

• Immunology
• Neurology
• Vaccinology

Background:

• Limited data exist on the relationship between COVID-19 vaccination and myasthenia gravis (MG).
• Investigating potential links between the Pfizer-BioNTech vaccine and MG is crucial for public health.
• Understanding vaccine safety in individuals with autoimmune conditions is essential.

Purpose of the Study:

• To evaluate the association between the Pfizer-BioNTech COVID-19 vaccine and new-onset myasthenia gravis (MG).
• To assess the impact of the Pfizer-BioNTech vaccine on MG exacerbation in patients with existing MG.
• To provide data on the safety profile of the Pfizer-BioNTech vaccine concerning MG.

Main Methods:

• A nested case-control study design was employed.
• Two cohorts were analyzed: a large cohort of adults without MG for new-onset cases and a cohort of MG patients for exacerbation.
• Exposure to the Pfizer-BioNTech COVID-19 vaccine within 4-8 weeks prior to outcomes was assessed and matched with controls.

Main Results:

• No statistically significant increased odds ratio for new-onset MG was observed following COVID-19 vaccination (OR 1.14, 95% CI 0.73-1.78).
• Similarly, no significant association was found between COVID-19 vaccination and MG exacerbation (OR 1.35, 95% CI 0.37-4.89).
• Sensitivity analyses and extended exposure windows (8 weeks) yielded consistent results.

Conclusions:

• The Pfizer-BioNTech COVID-19 vaccine is not associated with an increased risk of new-onset myasthenia gravis.
• The vaccine does not appear to exacerbate existing myasthenia gravis.
• Findings support the safety of the Pfizer-BioNTech vaccine concerning myasthenia gravis.